Drugs / AZD3965
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01791595 | Apr 2013 → Nov 2020 | Burkitt lymphoma, diffuse large B-cell lymphoma | Cancer Research UK | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3965 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01791595 ↗ |
| Action | Inhibit | “AZD3965 was developed as an inhibitor of this transporter” PMID 25957999 ↗ May 2015 |
| Modality | Small molecule | — CHEMBL3335793 ↗ |
| Route | Oral | “commenced dosing of 5 mg AZD3965 OD orally” NCT01791595 ↗ |